NCT04919109View on ClinicalTrials.gov

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

August 27, 2025

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

CodaVax-RSV

live attenuated vaccine against RSV

BIOLOGICAL

Normal Saline

Placebo comparator

Trial Locations (5)

68134

Velocity, Omaha

84088

Velocity, West Jordan

658510

Velocity, Lincoln

02818

Velocity, Providence

Unknown

University of Witwatersrand (WITS)/Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg

Sponsors

Lead Sponsor

Codagenix, Inc
All Listed Sponsors
lead

Codagenix, Inc

INDUSTRY